The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Lymphoma updates: CAR-T, brentuximab & nivolumab
Nathan Fowler, MD, University of Texas MD Anderson Cancer Center, Houston, TX, highlights key lymphoma news from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. These include updates on JCAR017 in non-Hodgkin lymphoma, and the combination of bretuximab vedotin and the checkpoint inhibitor nivolumab in Hodgkin lymphoma.
